文献速递精神分裂症与精神病性障碍

临床高危精神病个体突触多巴胺可用性的[11C]-(+)-PHNO PET及哌甲酯激发研究

Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study.
PubMed 文献 · Mol Psychiatry · 2020-11-05

该研究对14例未用药且无物质使用的临床高危(CHR)个体和14名匹配对照进行两次[11C]-(+)-PHNO PET扫描(基线和单次口服60 mg哌甲酯后),计算结合电位变化百分比(ΔBPND)作为突触多巴胺可用性指标。结果显示CHR组整体ΔBPND有高于对照的趋势(p=0.06),且该趋势完全由腹侧纹状体驱动(CHR组-34±14% vs 对照组-20±12%,p=0.023);腹侧纹状体ΔBPND与基线阴性症状严重程度呈强负相关(r=-0.66,p<0.01)。

要点

  • CHR个体腹侧纹状体突触多巴胺可用性较对照增高,整体趋势p=0.06,腹侧纹状体p=0.023。
  • 腹侧纹状体ΔBPND与基线阴性症状严重程度呈强负相关(r=-0.66,p<0.01)。
  • 其他脑区未见显著组间差异,转化者与非转化者比较样本量仅N=2,结果受限。

核心结论

  • CHR个体腹侧纹状体存在异常增高的多巴胺可用性,且与阴性症状严重程度呈负相关,提示中脑边缘多巴胺过度活跃可能早期参与CHR病理。

研究设计与样本

  • 研究纳入14例未用药、无物质使用的CHR个体和14名匹配对照,进行基线和单次口服60 mg哌甲酯后的两次[11C]-(+)-PHNO PET扫描。
  • 使用简化参考组织模型(以小脑为参考组织)计算BPND,以ΔBPND作为突触多巴胺可用性指标,采用线性混合模型进行组间比较。

主要发现

  • CHR组整体ΔBPND有高于对照的趋势(p=0.06),该趋势完全由腹侧纹状体驱动(CHR组-34±14%,对照组-20±12%,p=0.023)。
  • 其他脑区未见显著组间差异。
  • 转化者与非转化者各纹状体区多巴胺传递无显著差异,但样本量小(N=2)限制该发现。
  • CHR组腹侧纹状体ΔBPND与基线阴性症状严重程度呈强负相关(r=-0.66,p<0.01)。

关键数值与推荐

  • 组间比较采用线性混合模型,显著性阈值未明确报告。
  • 腹侧纹状体ΔBPND组间比较p=0.023,整体ΔBPND组间趋势p=0.06。
  • 腹侧纹状体ΔBPND与阴性症状相关分析r=-0.66,p<0.01。

临床怎么用

  • 腹侧纹状体突触多巴胺可用性可能作为CHR个体中脑边缘多巴胺过度活跃的早期影像学标志。
  • 腹侧纹状体多巴胺可用性与阴性症状的负相关提示其或与阴性症状维度相关,需进一步验证。
  • 当前证据尚不足以支持[11C]-(+)-PHNO PET用于临床预测转化,需纵向研究确认。

局限性

  • 转化者与非转化者比较样本量极小(N=2),无法得出转化预测相关结论。
  • 整体ΔBPND组间差异仅达趋势水平(p=0.06),统计效力有限。
  • 研究为横断面设计,无法确定多巴胺异常与临床结局的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients at clinical high-risk (CHR) for psychosis show elevations in [18F]DOPA uptake, an estimate of dopamine (DA) synthesis capacity, in the striatum predictive of conversion to schizophrenia. Intrasynaptic DA levels can be inferred from imaging the change in radiotracer binding at D2 receptors due to a pharmacological challenge. Here, we used methylphenidate, a DA reuptake inhibitor, and [11C]-(+)-PHNO, to measure synaptic DA availability in CHR both in striatal and extra-striatal brain regions. Fourteen unmedicated, nonsubstance using CHR individuals and 14 matched control subjects participated in the study. Subjects underwent two [11C]-(+)-PHNO scans, one at baseline and one following administration of a single oral dose (60 mg) of methylphenidate. [11C]-(+)-PHNO BPND, the binding potential relative to the nondisplaceable compartment, was derived using the simplified reference tissue model with cerebellum as reference tissue. The percent change in BPND between scans, ΔBPND, was computed as an index of synaptic DA availability, and group comparisons were performed with a linear mixed model. An overall trend was found for greater synaptic DA availability (∆BPND) in CHR than controls (p = 0.06). This was driven entirely by ∆BPND in ventral striatum (-34 ± 14% in CHR, -20 ± 12% in HC; p = 0.023). There were no significant group differences in any other brain region. There were no significant differences in DA transmission in any striatal region between converters and nonconverters, although this finding is limited by the small sample size (N = 2). There was a strong and negative correlation between ΔBPND in VST and severity of negative symptoms at baseline in the CHR group (r = -0.66, p < 0.01). We show abnormally increased DA availability in the VST in CHR and an inverse relationship with negative symptoms. Our results suggest a potential early role for mesolimbic dopamine overactivity in CHR. Longitudinal studies are needed to ascertain the significance of the differential topography observed here with the [18F]DOPA literature.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Girgis RR, Slifstein M, Brucato G, et al. Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study. Mol Psychiatry. 2020. PMID: 33154566. doi:10.1038/s41380-020-00934-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。